Flu Season Pushes Quidel Q4 Revenues up 40 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – An early and severe flu season drove Quidel's fourth-quarter revenues up 40 percent year over year, the company reported after the close of the market on Tuesday.

For the three months ended Dec. 31, 2012, Quidel posted $53.9 million in revenues, up from $38.4 million a year ago, and topping the consensus Wall Street estimate of $53.3 million. Flu-related products brought in $26.3 million in revenues during the quarter, company officials said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.